化疗对瘤型麻风患者针对酚糖脂-Ⅰ及85A和85B蛋白抗原的抗体水平的影响。

Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients.

作者信息

Drowart A, Chanteau S, Huygen K, De Cock M, Cartel J L, De Bruyn J, Launois P, Yernault J C, Van Vooren J P

机构信息

Chest Department, Hôpital Erasme, Brussels, Belgium.

出版信息

Int J Lepr Other Mycobact Dis. 1993 Mar;61(1):29-34.

PMID:8326178

Abstract

IgG antibodies against antigens 85A and 85B from Mycobacterium bovis BCG, IgM antibodies against phenolic glycolipid-I (PGL-I) and circulating PGL-I antigen were measured in the serum of 11 patients with lepromatous leprosy receiving multidrug therapy (MDT). Before treatment, 6 patients were reactive to antigen 85A, 10 patients to antigen 85B, and 11 patients to PGL-I; circulating PGL-I was detected in the sera of all of them. After 2 years of MDT PGL-I antigen could no longer be detected in all of the patients, except for two who were not compliant with treatment. IgG antibodies directed against the 85A and 85B antigens and IgM antibodies against the PGL-I antigen also decreased significantly during treatment but more slowly. The determination of circulating PGL-I antigen remains the most appropriate tool for monitoring lepromatous leprosy under MDT.

摘要

在接受多药联合治疗（MDT）的11例瘤型麻风患者的血清中，检测了针对卡介苗中抗原85A和85B的IgG抗体、针对酚糖脂-I（PGL-I）的IgM抗体以及循环PGL-I抗原。治疗前，6例患者对抗原85A呈反应性，10例患者对抗原85B呈反应性，11例患者对PGL-I呈反应性；所有患者血清中均检测到循环PGL-I。经过2年的MDT治疗，除2例未遵医嘱治疗的患者外，所有患者均未再检测到PGL-I抗原。在治疗期间，针对85A和85B抗原的IgG抗体以及针对PGL-I抗原的IgM抗体也显著下降，但下降速度较慢。循环PGL-I抗原的测定仍然是监测MDT下瘤型麻风的最合适工具。